Neuberger Berman Group
LSTA icon

Neuberger Berman Group’s Lisata Therapeutics LSTA Stock Holding History

Neuberger Berman Group’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-46
Closed -$38K – 1640
2013
Q2 		$38K Buy
+46
New +$40.4K ﹤0.01% 1566

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DC
Deere & Company Moline, Illinois $140M AUM 16.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Neuberger Berman Group's LSTA Position: Q3 2013 in Review

Neuberger Berman Group sold out of Lisata Therapeutics (LSTA) in Q3 2013, closing a stake of 46 shares — an estimated $38K sold.

Neuberger Berman Group first reported a position in LSTA in Q2 2013 and held it in 1 quarter. The position peaked at $38K in Q2 2013. 31 funds tracked by Wall St. Rank hold LSTA as of Q3 2013.

  • Neuberger Berman Group reported no remaining Lisata Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Neuberger Berman Group sold 46 Lisata Therapeutics shares in Q3 2013, an estimated $38K.
  • Neuberger Berman Group first reported a position in Lisata Therapeutics in Q2 2013 and held it in 1 quarter.
  • Neuberger Berman Group's Lisata Therapeutics position peaked at $38K in Q2 2013.
  • 31 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2013.

Based on Neuberger Berman Group's 13F filing for Q3 2013, filed 29 Oct 2013.